Keros to Receive $20M Milestone After First Patient Dosed in ELRiSE MF Phase 3 Trial

Keros expects a $20 million development milestone payment from Takeda following the first patient dosing in the ELRiSE MF Phase 3 trial.Key Highlights:Original SEC Filing: Keros Therapeutics, Inc. [ KROS ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider ver…